Biotech M&A is booming in 2026, driven by patent cliffs and market recovery, signaling the strongest dealmaking since 2019.
Read More

Biotech M&A is booming in 2026, driven by patent cliffs and market recovery, signaling the strongest dealmaking since 2019.
Read More